FDA CITES CYBERONICS FOR RESPONSES TO cGMP ISSUES

The GMP Letter
A A

Houston-based Cyberonics confirmed it has received a warning letter from the FDA that asserted the company’s responses to issues involving current good manufacturing practices (cGMPs) at its manufacturing facility have been insufficient.

To View This Article:

Login

Subscribe To The GMP Letter

Buy This Article Now

Add this article to your cart for $10.00